Back

Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis

25 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Current and novel antiplatelet therapy in cardiovascular disease Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Livia Stanger

University of Michigan, Ann Arbor (United States of America)

5 More presentations in this session

Presentation thumbnail
HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner
Associate Professor M. Holinstat (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Variability of the antithrombotic effect of acetylsalicylic acid with the administration of different dosages: reality or myth?
Doctor J. Lima Lopes (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Antiplatelet effect of acetylsalicylic acid in patients early after cardiac valve surgery: comparative investigation of the impairment of platelet inhibition by dipyrone versus acetaminophen
Professor D. Trenk (Bad Krozingen, DE)
Abstract Slides Video
Presentation thumbnail
CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel
Doctor E. Magavern (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Current and novel antiplatelet therapy in cardiovascular disease

The Event

Event poster

ESC Congress 2023

25 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis
thumbnail
Congress Session
Biotherapies in cardiovascular disease: from bench to bedside
thumbnail
Congress Presentation
HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources